Infection control wins stimulus funds

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

An investigator at Fred Hutchinson Cancer Center in Seattle has earned a $1.74 million grant under the American Recovery & Reinvestment Act of 2009.

An investigator at Fred Hutchinson Cancer Center in Seattle has earned a $1.74 million grant under the American Recovery & Reinvestment Act of 2009.

Recipient Colleen Delaney, MD, is an assistant member in the Fred Hutchinson center’s clinical research division. Her goal is to find to ways to reduce the risk of infection, and early death, in patients who receive cord blood transplants.

In her ongoing research, Dr. Delaney developed a novel culture methodology, which demonstrated that neutrophils can be generated from a single unit of cord blood. In addition, these cells are capable of rapid recovery when infused in the clinical setting. These findings could change the way transplant is done.

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
2 experts in this video
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
2 experts in this video
Related Content